Sarcoidosis Market Report 2026

Sarcoidosis Market Overview

• Sarcoidosis market size has reached to $34.37 billion in 2025 • Expected to grow to $69.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.2% • Growth Driver: Increasing Focus On Personalized Medicine Fueling The Growth Of The Market Due To Targeted Treatment And Improved Patient Outcomes • Market Trend: Innovative Biologics Transforming Sarcoidosis Treatment With Targeted Immunotherapy Advances • Europe was the largest region in 2025.

What Is Covered Under Sarcoidosis Market?

Sarcoidosis is a complex inflammatory disease characterized by the formation of granulomas, small clumps of immune cells that can develop in various organs, most commonly the lungs and lymph nodes, potentially leading to organ dysfunction, respiratory issues, or systemic complications, with its exact cause remaining unknown but suspected to involve an abnormal immune response to environmental or genetic factors. The main types of sarcoidosis are pulmonary sarcoidosis, ocular sarcoidosis, neurosarcoidosis, cardiac sarcoidosis, musculoskeletal sarcoidosis, cutaneous sarcoidosis, renal sarcoidosis, hepatic sarcoidosis, and sarcoidosis of the spleen and bone marrow. Pulmonary sarcoidosis is a chronic inflammatory disease characterized by the formation of granulomas small clumps of immune cells in the lungs, leading to respiratory symptoms such as cough, shortness of breath, and potential lung fibrosis if left untreated. These are diagnosed with various methods, including imaging techniques, biopsies, and blood tests, and have treatment types such as corticosteroids, immunosuppressive agents, biologics, and anti-malarial drugs, including routes of administration such as oral, parenteral, and others, and are used in hospitals and clinics, surgical centers, diagnostic centers, and others.

What Is The Sarcoidosis Market Growth Forecast?

The sarcoidosis market size is expected to see rapid growth in the next few years. It will grow to $69.92 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to development of novel biologics and immunomodulators, increasing focus on steroid-sparing treatment options, rising prevalence of chronic and multi-organ sarcoidosis, expansion of clinical research in rare inflammatory diseases, improving patient access to specialty care centers. Major trends in the forecast period include increasing off-label use of biologics for refractory sarcoidosis, growing focus on pulmonary sarcoidosis management, rising adoption of corticosteroid-sparing treatment regimens, increased use of imaging and biomarker-based disease monitoring, expanding clinical trials for novel anti-inflammatory therapies.

Global Sarcoidosis Market Segmentation

1) By Type: Pulmonary Sarcoidosis, Ocular Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoidosis, Musculoskeletal Sarcoidosis, Cutaneous Sarcoidosis, Renal Sarcoidosis, Hepatic Sarcoidosis, Sarcoidosis Of The Spleen And Bone Marrow 2) By Diagnostic Method: Imaging Technique, Biopsy, Blood Tests 3) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Biologics, Anti-Malarial Drugs 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 5) By End Uses: Hospitals And Clinics, Surgical Centers, Diagnostic Centers, Other End Uses Subsegments: 1) By Pulmonary Sarcoidosis: Acute Pulmonary Sarcoidosis, Chronic Pulmonary Sarcoidosis, Fibrotic Pulmonary Sarcoidosis 2) By Ocular Sarcoidosis: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis, Optic Neuropathy 3) By Neurosarcoidosis: Meningeal Neurosarcoidosis, Cranial Nerve Neurosarcoidosis, Peripheral Neuropathy, Spinal Cord Involvement, Hypothalamic-Pituitary Involvement 4) By Cardiac Sarcoidosis: Atrioventricular Block, Ventricular Arrhythmias, Heart Failure, Myocarditis, Sudden Cardiac Arrest 5) By Musculoskeletal Sarcoidosis: Arthritis, Myopathy, Bone Lesions 6) By Cutaneous Sarcoidosis: Lupus Pernio, Erythema Nodosum, Papular Sarcoidosis, Plaque Sarcoidosis, Subcutaneous Sarcoidosis 7) By Renal Sarcoidosis: Granulomatous Interstitial Nephritis, Nephrocalcinosis, Hypercalciuria-Induced Kidney Disease 8) By Hepatic Sarcoidosis: Granulomatous Hepatitis, Portal Hypertension, Hepatic Fibrosis 9) By Sarcoidosis Of The Spleen And Bone Marrow: Splenomegaly, Pancytopenia, Bone Marrow Granulomas

What Is The Driver Of The Sarcoidosis Market?

The increasing focus on personalized medicine is expected to fuel the growth of the sarcoidosis market going forward. Personalized medicine is an advanced approach to medical treatment that tailors’ therapeutic strategies to individual patients based on their genetic profile, biomarkers, environmental factors, and lifestyle, ensuring more precise, effective, and targeted interventions. The demand for personalized medicine is growing as it allows treatments to be tailored to an individual's genetic makeup and biological profile by enhancing effectiveness while reducing side effects. Personalized medicine in sarcoidosis tailors treatment based on genetic, biomarker, and clinical profiling to improve efficacy and reduce side effects. This approach enhances targeted therapy, addressing disease heterogeneity and individual patient responses. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA), a US-based government regulatory agency, approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the sarcoidosis industry.

Key Players In The Global Sarcoidosis Market

Major companies operating in the sarcoidosis market are Pfizer Inc, F Hoffmann La Roche AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc, UCB Pharma, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Limited, Mallinckrodt Pharmaceuticals, Xentria Inc, Molecure SA, Relief Therapeutics Holding AG, Sanofi SA, Amgen Inc, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd

Global Sarcoidosis Market Trends and Insights

Major companies operating in the sarcoidosis market are focusing on developing innovative products, such as anti-TNFα monoclonal antibody therapy, to introduce a novel biologic treatment that addresses a critical unmet medical need in managing inflammatory diseases. Anti-tumor necrosis factor-alpha (anti-TNFα) monoclonal antibody therapy is a targeted immunotherapy that involves the use of monoclonal antibodies to inhibit TNFα, a pro-inflammatory cytokine, thereby reducing inflammation and managing autoimmune diseases. For instance, in November 2023, Xentria, Inc., a US-based clinical-stage biotherapeutics company, achieved a significant milestone as its lead candidate, XTMAB-16, received Orphan Drug Designation from the European Medicines Agency (EMA). Simultaneously, the company initiated its global clinical study for pulmonary sarcoidosis with the enrollment of the first patient. XTMAB-16, a monoclonal antibody targeting tumor necrosis factor-alpha (TNFα), is being investigated for its potential to modulate inflammatory pathways in pulmonary sarcoidosis, providing a targeted alternative to corticosteroid-based therapies. This regulatory recognition and clinical advancement highlight the growing global focus on innovative biologics for rare diseases, reinforcing Xentria’s commitment to addressing unmet medical needs with transformative treatment options.

What Are Latest Mergers And Acquisitions In The Sarcoidosis Market?

In June 2023, Xentria Inc., a US-based biotherapeutics company, partnered with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. Under this collaboration, Meitheal Pharmaceuticals gains exclusive commercialization rights for XTMAB-16 in North America, while Xentria continues to lead its clinical development and regulatory advancement. This partnership aims to expand market access and enhance treatment options for patients with pulmonary sarcoidosis by leveraging Xentria’s expertise in biologics and Meitheal’s strong commercialization capabilities. Meitheal Pharmaceuticals, Inc. is a US-based biopharmaceutical company that specializes in developing and commercializing generic injectables, fertility treatments, biologics, and branded products.

Regional Outlook

Europe was the largest region in the sarcoidosis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sarcoidosis Market?

The sarcoidosis market includes revenues earned by entities by providing services such as diagnostic tests, laboratory testing, gene therapies, disease management services, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The sarcoidosis market also includes sales of corticosteroids, immunosuppressive agents, and antimalarial drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sarcoidosis Market Report 2026?

The sarcoidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sarcoidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.